Can-Fite BioPharma American Depositary Shares
CANF
11 hedge funds and large institutions have $1.62M invested in Can-Fite BioPharma American Depositary Shares in 2024 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
53% more capital invested
Capital invested by funds: $1.06M → $1.62M (+$559K)
38% more funds holding
Funds holding: 8 → 11 (+3)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$322K |
| 2 |
Morgan Stanley
New York
|
+$28.4K |
| 3 |
HF
HRT Financial
New York
|
+$25.5K |
| 4 |
VF
Virtu Financial
New York
|
+$24.6K |
| 5 |
AWM
Activest Wealth Management
Aventure,
Florida
|
+$473 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$31.5K |
| 2 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$7.29K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$4.82K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $1.34M | +$322K | +6,803 | +36% |
|
|
2
Morgan Stanley
New York
| $175K | +$28.4K | +600 | +22% |
|
|
3
RhumbLine Advisers
Boston,
Massachusetts
| $39.7K | -$7.29K | -154 | -17% |
|
|
VF
4
Virtu Financial
New York
| $27K | +$24.6K | +521 | New |
|
|
HF
5
HRT Financial
New York
| $27K | +$25.5K | +540 | New |
|
6
Fifth Third Bancorp
Cincinnati,
Ohio
| $7.74K | – | – | – |
|
7
National Bank of Canada
Montreal,
Quebec, Canada
| $1.55K | – | – | – |
|
8
Citigroup
New York
| $1.43K | – | – | – |
|
|
AWM
9
Activest Wealth Management
Aventure,
Florida
| $516 | +$473 | +10 | New |
|
10
Osaic Holdings
Scottsdale,
Arizona
| $477 | +$426 | +9 | New |
|
|
TWC
11
TD Waterhouse Canada
Toronto,
Ontario, Canada
| $52 | +$47 | +1 | New |
|
|
12
Citadel Advisors
Miami,
Florida
| – | -$31.5K | -709 | Closed |
|
|
13
UBS Group
Zurich,
Switzerland
| – | -$4.82K | -109 | Closed |
|
CANF Hedge Fund Activity: Q2 2024 in Review
11 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q2 2024, worth a combined $1.62M — up 53% from $1.06M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CANF positions and 2 closed out — a net gain of 3 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Armistice Capital, adding an estimated $322K. The largest seller was Citadel Advisors, exiting entirely with an estimated $31.5K sold.
- 11 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q2 2024, up from 8 in Q1 2024.
- Funds reported $1.62M of Can-Fite BioPharma American Depositary Shares stock for Q2 2024, up 53% quarter-over-quarter.
- 5 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q2 2024 and 2 closed out, a net change of +3 holders.
- The largest Can-Fite BioPharma American Depositary Shares buyer in Q2 2024 was Armistice Capital, an estimated $322K added.
- The largest Can-Fite BioPharma American Depositary Shares seller in Q2 2024 was Citadel Advisors, an estimated $31.5K sold.
Based on aggregated 13F filings for Q2 2024.